6920 Little Brook Ct, Elkridge MD 21075, USA

Welcome To

LTN Pharma

Unravelling the Potential of Novel Therapeutic Agents

Contact Us
About us

LTN Pharma

LTN Pharmaceuticals, Inc. is a Delaware corporation based in Baltimore, USA, dedicated to developing novel therapeutic treatments for diseases within the global healthcare market. LTN Pharma is committed to innovation and cutting-edge research through R&D, with the goal of offering competitive products to promote a healthy human population while generating high returns for its investors. LTN Pharma collaborates with leading research centers enhancing its capacity for R&D through access to renowned experts and the latest state-of-the-art research facilities. This will drive LTN Pharma’s quest to bring innovative therapeutics to market.

LTN Pharma

Pipeline

Opportunity and Need for Better Treatments

Prostate Cancer is in Need for Better Treatments

The Current Standard of Care especially in LMICs is Marginal at Best

Prostate cancer is a highly metastatic, and surgery (castration), is not always enough

U.S/global Large Market Potential for Prostate Cancer Therapeutic Options

virtually all patients will eventually progress on these therapies and most will ultimately die of treatment-refractory metastatic disease. 

LTN Pharma

Clinical Trials

LTN Pharma's Approach

  • Pragmatic phase III trial in LMIC settings, taking into consideration the barriers in obtaining optimal care.
  • If effective, will be a major breakthrough in treating and improving the quality of life of persons living with prostate cancer in the Caribbean, Africa and South America, initially, &
  • Globally upon the completion of the largescale Phase III clinical trials with the salt form of galeterone.
Media

News and Publications

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Read More

Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer

Read More

Large-scale synthesis of galeterone and lead next generation galeterone analog VNPP433-3β

Read More

Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer

Read More

Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin

Read More

Galeterone for the treatment of advanced prostate cancer: the evidence to date

Read More

Newsletter

Subscribe to Receive News from LTN Pharma